Mutations in exon 1 highlight the role of MED12 in uterine leiomyomas

Human Mutation

Volumn 35, Issue 9, 2014, Pages 1136-1141

  Kämpjärvi, Kati ^a   Park, Min Ju ^b   Mehine, Miika ^a   Kim, Nam Hee ^b   Clark, Alison D ^b   Bützow, Ralf ^c   Böhling, Tom ^c   Böhm, Jan ^d   Mecklin, Jukka Pekka ^e   Järvinen, Heikki ^c   Tomlinson, Ian P M ^f   van der Spuy, Zephne M ^g   Sjöberg, Jari ^c   Boyer, Thomas G ^b   Vahteristo, Pia ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b University of Texas Health Science Center   (United States)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^e UNIVERSITY OF EASTERN FINLAND   (Finland)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Benign tumor; Cancer; MED12; Somatic mutation; Uterine leiomyoma

Indexed keywords

CYCLIN C; CYCLIN DEPENDENT KINASE 19; CYCLIN DEPENDENT KINASE 8; MED12 PROTEIN; PHOSPHOTRANSFERASE; TRANSCRIPTOME; UNCLASSIFIED DRUG; MED12 PROTEIN, HUMAN; MEDIATOR COMPLEX; PROTEIN BINDING;

ARTICLE; CARCINOGENESIS; COLORECTAL CANCER; ENDOMETRIUM POLYP; ENZYME ACTIVITY; EXON; GENE EXPRESSION; GENE MUTATION; GENETIC SCREENING; IMMUNOPRECIPITATION; INDEL MUTATION; LEIOMYOMA; LEIOMYOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERUS MYOMA; CELL LINE; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION STUDY; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; UTERUS CANCER;

CELL LINE; CLUSTER ANALYSIS; EXONS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; HUMANS; LEIOMYOMA; MEDIATOR COMPLEX; MUTATION; PROTEIN BINDING; UTERINE NEOPLASMS;

EID: 84906044029     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22612     Document Type: Article

References (32)

1. Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomäki P, Chadwick RB, Kääriäinen H, Eskelinen M, Järvinen H, Mecklin JP, de la Chapelle A. 1998. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 338:1481-1487.
2. Borggrefe T, Davis R, Erdjument-Bromage H, Tempst P, Kornberg RD. 2002. A complex of the Srb8, -9, -10, and -11 transcriptional regulatory proteins from yeast. J Biol Chem 277:44202-44207.
3. Cancer Genome Atlas Network. 2012. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330-337.
4. Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. 2003. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 188:100-107.
5. de Graaff MA, Cleton-Jansen AM, Szuhai K, Bovee JV. 2013. Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity. Hum Pathol 44:1597-1604.
6. Flynn M, Jamison M, Datta S, Myers E. 2006. Health care resource use for uterine fibroid tumors in the United States. Am J Obstet Gynecol 195:955-964.
7. Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, Cole C, Kok CY, Jia M, Ewing R, Menzies A, Teaque JW, Stratton MR, et al. 2010. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res 38:D652-D657.
8. Jacoby VL, Autry A, Jacobson G, Domush R, Nakagawa S, Jacoby A. 2009. Nationwide use of laparoscopic hysterectomy compared with abdominal and vaginal approaches. Obstet Gynecol 114:1041-1048.
9. Je EM, Kim MR, Min KO, Yoo NJ, Lee SH. 2012. Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors. Int J Cancer 2012:E1044-E1047.
10. Kämpjärvi K, Mäkinen N, Kilpivaara O, Arola J, Heinonen HR, Böhm J, Abdel-Wahab O, Lehtonen HJ, Pelttari LM, Mehine M, Schrewe H, Nevanlinna H, et al. 2012. Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer. Br J Cancer 107:1761-1765.
11. Kim S, Xu X, Hecht A, Boyer TG. 2006. Mediator is a transducer of Wnt/beta-catenin signaling. J Biol Chem 281:14066-14075.
12. Kiuru M, Lehtonen R, Arola J, Salovaara R, Järvinen H, Aittomäki K, Sjöberg J, Visakorpi T, Knuutila S, Isola J, Delahunt B, Herva R, et al. 2002. Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res 62:4554-4557.
13. Mäkinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, Lehtonen HJ, Gentile M, Yan J, Enge M, Taipale M, Aavikko M, Katainen R, et al. 2011a. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 334:252-255.
14. Mäkinen N, Heinonen HR, Moore S, Tomlinson IP, van der Spuy ZM, Aaltonen LA. 2011b. MED12 exon 2 mutations are common in uterine leiomyomas from South African patients. Oncotarget 2:966-969.
15. Mäkinen N, Vahteristo P, Kämpjärvi K, Arola J, Bützow R, Aaltonen LA. 2013. MED12 exon 2 mutations in histopathological uterine leiomyoma variants. Eur J Hum Genet 21:1300-1303.
16. Markowski DN, Bartnitzke S, Loning T, Drieschner N, Helmke BM, Bullerdiek J. 2012a. MED12 mutations in uterine fibroids-their relationship to cytogenetic subgroups. Int J Cancer 131:1528-1536.
17. Markowski DN, Huhle S, Nimzyk R, Stenman G, Loning T, Bullerdiek J. 2012b. MED12 mutations occurring in benign and malignant mammalian smooth muscle tumors. Genes Chromosomes Cancer 52:297-304.
18. Matsubara A, Sekine S, Yoshida M, Yoshida A, Taniguchi H, Kushima R, Tsuda H, Kanai Y. 2012. Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours. Histopathology 62:657-661.
19. McGuire MM, Yatsenko A, Hoffner L, Jones M, Surti U, Rajkovic A. 2012. Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas. PLoS One 7:e33251.
20. Mehine M, Kaasinen E, Mäkinen N, Katainen R, Kämpjärvi K, Pitkänen E, Heinonen HR, Bützow R, Kilpivaara O, Kuosmanen A, Ristolainen H, Gentile M, et al. 2013. Characterization of uterine leiomyomas by whole-genome sequencing. N Engl J Med 369:43-53.
21. Parker WH. 2007. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril 87:725-736.
22. Perot G, Croce S, Ribeiro A, Lagarde P, Velasco V, Neuville A, Coindre JM, Stoeckle E, Floquet A, Macgrogan G, Chibon F. 2012. MED12 alterations in both human benign and malignant uterine soft tissue tumors. PLoS One 7:e40015.
23. Ravegnini G, Marino-Enriquez A, Slater J, Eilers G, Wang Y, Zhu M, Nucci MR, George S, Angelini S, Raut CP, Fletcher JA. 2012. MED12 mutations in leiomyosarcoma and extrauterine leiomyoma. Mod Pathol 26:743-749.
24. Rieker RJ, Agaimy A, Moskalev EA, Hebele S, Hein A, Mehlhorn G, Beckmann MW, Hartmann A, Haller F. 2013. Mutation status of the mediator complex subunit 12 (MED12) in uterine leiomyomas and concurrent/metachronous multifocal peritoneal smooth muscle nodules (leiomyomatosis peritonealis disseminata). Pathology 45:388-392.
25. Salovaara R, Loukola A, Kristo P, Kääriäinen H, Ahtola H, Eskelinen M, Härkönen N, Julkunen R, Kangas E, Ojala S, Tulikoura J, Valkamo E, et al. 2000. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 18:2193-2200.
26. Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H, Van de Ven WJ. 1995. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat Genet 10:436-444.
27. Schwetye KE, Pfeifer JD, Duncavage EJ. 2014. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors. Hum Pathol 45:65-70.
28. Segars JH, Parrott EC, Nagel JD, Guo XC, Gao X, Birnbaum LS, Pinn VW, Dixon D. 2014. Proceedings from the third national institutes of health international congress on advances in uterine leiomyoma research: comprehensive review, conference summary and future recommendations. Hum Reprod Update 20:309-333.
29. Taatjes DJ. 2010. The human mediator complex: a versatile, genome-wide regulator of transcription. Trends Biochem Sci 35:315-322.
30. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, Roylance RR, Olpin S, et al. 2002. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30:406-410.
31. Turunen M, Spaeth JM, Keskitalo S, Park MJ, Kivioja T, Clark AD, Mäkinen N, Gao F, Palin K, Nurkkala H, Vähärautio A, Aavikko M, et al. 2014. Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity. Cell Rep 7:654-660.
32. Ylisaukko-oja SK, Kiuru M, Lehtonen HJ, Lehtonen R, Pukkala E, Arola J, Launonen V, Aaltonen LA. 2006. Analysis of fumarate hydratase mutations in a population-based series of early onset uterine leiomyosarcoma patients. Int J Cancer 119:283-287.